What is the optimal neoadjuvant systemic therapy dosing and schedule in a patient with undifferentiated pleomorphic sarcoma of the extremity for whom up-front surgery would portend significant morbidity?

Assuming the patient has no major co-morbidities, has normal PS and organ function, we would give AI (75/10) q 3 weeks, with q 2 cycles re-imaging, for up to 6 cycles based on response/tolerance. This would then be followed by pre-op XRT and then WLE, assuming it has become feasible.